Prostate Tissue Banking

  • Harveer Dev
  • Prasanna Sooriakumaran
  • Ashutosh K. TewariEmail author


As the most common non-dermatologic malignancy affecting males in the Western world, and the second leading cause of male cancer-related deaths, the importance of prostate cancer research needs little justification [1]. Epidemiologic reports have described the significant heritability of such malignancies, with one twin-study attributing 42 % (CI 29–50 %) of prostate cancer cases to heritable factors [2]. Genome-wide linkage analyses of germline single nucleotide polymorphisms (SNPs) continue to uncover many low-risk genetic associations with prostate cancer [3]. These findings are being supplemented with expression arrays in an effort to identify individual somatic mutations such as TMPRSS2-ERG gene fusions [4] as well as more global gene expression profiles.


Prostate Cancer Radical Prostatectomy Prostate Cancer Case Global Gene Expression Profile Robotic Prostatectomy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277.PubMedCrossRefGoogle Scholar
  2. 2.
    Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K. Environmental and heritable factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343(2):78–85.PubMedCrossRefGoogle Scholar
  3. 3.
    Witte J. Prostate cancer genomics: toward a new understanding. Nat Rev Genet. 2009;10(2):77–82.PubMedCrossRefGoogle Scholar
  4. 4.
    Setlur SR, et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst. 2008;100:815–25.PubMedCrossRefGoogle Scholar
  5. 5.
    Zheng SL, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med. 2008;358:910–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 2008;8:497–511.PubMedCrossRefGoogle Scholar
  7. 7.
    Tewari AK, Rao S, Martinez-Salamanca JI, Leung R, Ramanathan R, Mandhani A, Vaughan ED, Menon M, Horninger W, Tu J, Bartsch G. Cancer control and the preservation of neurovascular tissue: how to meet competing goals during robotic radical prostatectomy. BJU Int. 2008;101(8):1013–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Hollenbeck BK, Bassily N, Wei JT, Montie JE, Hayasaka S, Taylor JM, Rubin MA. Whole mounted radical prostatectomy specimens do not increase detection of adverse pathological features. J Urol. 2000;164(5):1583–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Dev H, Rickman D, Sooriakumaran P, Srivastava A, Grover S, Leung R, Kim R, Kitabayashi N, Esqueva R, Park K, Padilla J, Rubin M, Tewari A. Biobanking after robotic-assisted radical prostatectomy: a quality assessment of providing prostate tissue for RNA studies. Prostate Cancer Prostatic Dis. J Transl Med. 2011 Jul 26;9:121.Google Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • Harveer Dev
    • 1
  • Prasanna Sooriakumaran
    • 2
  • Ashutosh K. Tewari
    • 3
    Email author
  1. 1.Department of SurgeryCambridge University Hospital NHS Foundation TrustCambridgeUK
  2. 2.Department of UrologyWeill Cornell Medical CollegeNew YorkUSA
  3. 3.Department of UrologyInstitute of Prostate Cancer and Lefrak Center for Robotic Surgery, James Buchanan Brady Foundation, Weill Medical College of Cornell UniversityNew YorkUSA

Personalised recommendations